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Development of the chronic obstructive
pulmonary disease morning symptom diary
(COPD-MSD)
Gary Globe1*, Brooke Currie2, Nancy Kline Leidy2, Paul Jones3, David Mannino4, Fernando Martinez5, Paul Klekotka6,
Sean O’Quinn7, Niklas Karlsson8 and Ingela Wiklund2

Abstract
Background: The morning tends to be the most difficult time of day for many patients with chronic obstructive
pulmonary disease (COPD) when symptoms can limit one’s ability to perform even simple activities. Morning
symptoms have been linked to higher levels of work absenteeism, thereby increasing the already substantial
economic burden associated with COPD. A validated patient-reported outcome (PRO) instrument designed to
capture morning symptoms will allow for a more comprehensive approach to the evaluation of treatment benefit
in COPD clinical trials.
Methods: A qualitative interview study was conducted among a sample of symptomatic adults with COPD.
Concept elicitation interviews (n = 35) were conducted to identify COPD morning symptoms, followed by cognitive
interviews (n = 21) to ensure patient comprehension of the items, instructions and response options of the draft
COPD Morning Symptom Diary (COPD-MSD). All interview transcript data were coded using ATLAS.ti software for
content analysis.
Results: Mean age of the concept elicitation and cognitive interview sample was 65.0 years (±7.5) and 62.3 years
(±8.3), respectively. The study sample represented the full range of COPD severity (Global Initiative for Chronic Lung
Disease [GOLD] classifications I–IV) and included a mix of racial backgrounds, employment status and educational
achievement. During the concept elicitation interviews, the three most frequently reported morning symptoms
were shortness of breath (n = 35/35; 100 %), phlegm/mucus (n = 31/35; 88.6 %), and cough (n = 30/35; 85.7 %).
A group of clinical and instrument development experts convened to review the concept elicitation data and
develop the initial 32-item draft COPD-MSD. Cognitive interviews indicated subjects found the draft COPD-MSD to
be comprehensive, clear, and easy to understand. The COPD-MSD underwent minor editorial revisions and
streamlining based on cognitive interviews and input from the experts to yield the final 19-item daily diary.
Conclusions: This study supports the content validity of the new COPD-MSD and positions the diary for
quantitative psychometric testing.
Keywords: COPD, Patient-reported outcome, COPD-MSD, Morning, Symptoms
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Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of death globally despite the fact that it is
both preventable and treatable [1]. In addition to high
mortality rates, COPD is associated with substantial
morbidity as well as economic burden, including direct
and indirect healthcare costs [2–4]. COPD is characterized by a number of symptoms, including shortness of
breath (SOB), cough, sputum production, wheezing,
chest tightness, and fatigue [3]. COPD symptoms are
often associated with a decline in functional status and
physical activity, and therefore a decline in patient
health-related quality of life [5, 6].
Symptoms can vary greatly in severity and frequency
and these variations can occur from day-to-day or over
the course of a single day [7, 8]. Several studies have
shown that, symptomatically, the morning tends to be
the most difficult time of day for individuals with COPD
and that morning symptoms considerably limit one’s
ability to perform simple morning activities [7, 9–11].
Instruments which focus on activities that are integral to
daily life are more likely to capture the magnitude of deteriorations and improvements in breathlessness than instruments focusing on nonessential activities [5]. This
makes the morning period a particularly good time of
the day to ask about activities and symptoms given that
certain, basic activities of daily living cannot be avoided
in most cases (e.g., getting out of bed, self-care activities). Research has also indicated that patients who experience morning symptoms are at higher risk for
exacerbations and are more likely to use their rescue inhaler [11]. Furthermore, morning symptoms, which can
be a particular challenge for subjects on the severe end
of the disease spectrum, lead to higher levels of work absenteeism for individuals who are gainfully employed
[11, 12]. This all points to morning symptoms as an important aggravating factor in the already substantial economic burden associated with COPD.
A few patient-reported outcome (PRO) measures have
been developed in recent years to assess COPD patients’
ability to perform morning activities and to evaluate
their morning symptoms. For example, the Capacity of
Daily Living during the Morning (CDLM) questionnaire
and the Global Chest Symptoms Questionnaire (GCSQ)
were developed in parallel and as complimentary assessments of morning symptoms and one’s ability to
complete activities [13]. Although psychometric testing
supported the reliability and responsiveness of both,
these questionnaires were developed among a relatively
small sample of individuals and saturation of concepts
was not expressly demonstrated – an important requirement outlined in the Food and Drug Administration’s
(FDA) guidance for the development of PROs [14] –
thus, the CDLM and GCSQ may not be appropriate for
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use in drug development trials to support labeling claims
[11, 15]. A relatively new PRO, the Early Morning Symptoms of COPD Instrument (EMSCI), was reported in
two abstracts [16, 17]. The EMSCI was designed to
measure the frequency and severity of early morning
symptoms in subjects with COPD [17]. The EMSCI recently underwent psychometric evaluation in a COPD
population enrolled in a Phase 3 clinical trial [16] and although the results suggested good quantitative evaluation properties, the measure is not publically available.
Another available measure of respiratory symptoms in
COPD is a derivative of the Exacerbations of Chronic
Pulmonary Disease Tool (EXACT), the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) scale. This
diary assesses 11 respiratory symptoms of COPD. The
development of the E-RS followed good research practices and FDA guidelines for PRO measures [14] and results from clinical trials suggest that the scale is a
reliable, valid and responsive measure of COPD symptoms [18, 19]. The EXACT/E-RS is administered daily in
the evening to capture respiratory symptoms over a 24-h
period without explicit reference to morning symptoms.
Although the E-RS is a comprehensive symptom measure, clinical trials may benefit from additional diary
questions about morning symptoms for added precision
and sensitivity to treatment effects specific to this time
of day.
With the morning period being an especially difficult time for some individuals as they experience
potentially more frequent and more severe symptoms,
having a measure that focuses purely on this sensitive
period of the day is an important need that should be
met. Thus, given the significance of morning symptoms to patients with COPD, the development of a
robust PRO instrument designed to capture morning
COPD symptoms in clinical trials as a measure of
treatment benefit, with a view to supporting labeling
claims, is warranted.

Methods
An iterative, qualitative process was undertaken to develop the COPD Morning Symptom Diary (COPDMSD). The process included a review of the literature,
which informed the development of an interview guide,
input from subjects through qualitative interviews, and
discussion with experts (Fig. 1). This paper details the
methods, results and conclusions from the two phases of
qualitative subject interviews to assure content validity
of the final instrument: concept elicitation to capture
morning symptom experiences as described by COPD
subjects and cognitive interviews to assess patient interpretation of the draft instrument.
Subjects were recruited from 8 pulmonary sites located across the United States (US). Six sites recruited
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Fig. 1 Instrument Development Steps for the COPD Morning Symptom COPD-MSD

35 subjects for the concept elicitation phase; 4 sites recruited 21 subjects for the cognitive interview phase.
The study protocol (#12198) was reviewed and approved
by Ethical & Independent Review Services – a central institutional review board. Written informed consent was
obtained from subjects prior to subjects completing any
study procedures.

Inclusion/exclusion criteria for concept elicitation and
cognitive interviews

Subjects were included if they met the following criteria:
1) aged ≥40 and ≤75 years at time of screening; 2) diagnosis of COPD with chart-documented postbronchodilator FEV1/forced vital capacity (FVC) < 0.70;
3) history of cigarette smoking >10 pack years at time of
screening; 4) experienced at least one COPD symptom
(i.e., cough, shortness of breath, or coughing up mucus/
phlegm/sputum) at least 2–3 times a week over the past
month that resulted in an impact on the typical morning
routine (e.g., getting dressed, moving around the home,
preparing breakfast); 5) Modified Medical Research
Council (mMRC) Dyspnea Scale score ≥1 at time of
screening; 6) history of at least one COPD exacerbation
(COPD worsening treated with systemic corticosteroids
and/or antibiotics) within the 12 months prior to screening (did NOT apply to subjects classified as Global Initiative for Chronic Obstructive Lung Disease [GOLD] I);
7) ability to read, speak and write English; and 8) were
willing to provide written informed consent.

Subjects were excluded if they met the following criteria: 1) primary diagnosis of asthma or any other
chronic respiratory disease other than COPD; 2) COPD
for any etiology other than tobacco cigarette smoking; 3)
congestive heart failure or coronary artery disease with
uncontrolled symptoms; 4) treated with chronic systemic
corticosteroids as defined by daily use (or equivalent) for
at least half of the time in the last year before screening;
5) diagnosis of any other systemic disease considered by
the investigator to be clinically significant and unstable/
uncontrolled (e.g., Crohn’s disease); 6) participated in a
COPD investigational device or drug study within the
previous 30 days or planned to begin a new treatment
for COPD between the time of screening/enrollment
and the study visit; or 7) any other clinically relevant
and/or serious concurrent medical condition including,
but not limited to visual problems or severe mental illness or cognitive impairment which, in the opinion of
the investigator, would interfere with his or her ability to
participate in an interview and/or complete the study
procedures. Subjects who participated in a concept
elicitation interview were excluded from participating in
a cognitive interview.
Measures and methods

Each phase of qualitative interviews involved one
study visit in which subjects with COPD participated
in a semi-structured interview and completed several
self-administered questionnaires including the COPD
Assessment Test (CAT), [20] the mMRC Dyspnea
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Scale, [21, 22] the St. Georges Respiratory Questionnaire
for COPD patients (SGRQ-C), [23] and a sociodemographic form. In addition, site clinicians completed a clinical form to capture clinical characteristics for each subject
including, but not limited to, date of COPD diagnosis,
GOLD stage for airway obstruction, recent pulmonary
function testing results (i.e., pre- and post-bronchodilator:
forced expiratory volume in one second (FEV1), FEV1 predicted, FVC), number of hospitalizations in past 6 months,
key comorbid conditions, and any COPD medications. The
clinical form also incorporated the clinician-completed version of the mMRC Dyspnea Scale.
Semi-structured discussion guides were developed –
one for the concept elicitation interviews and one for the
cognitive interviews – to facilitate general consistency
across interviews. Concept elicitation interviews were
open-ended, designed to engage the subject in a discussion
of their morning symptoms without leading or prompting
with specific symptoms. Following this open dialogue,
subjects were asked about specific symptoms commonly
associated with COPD that were not spontaneously mentioned by the subject. Results formed the basis of a draft
instrument tested during cognitive interviews with a new
set of subjects. For these interviews, subjects first completed the COPD-MSD in its entirety and then interviewers reviewed the diary questions one-by-one to gather
subjects’ interpretation and thought process around their
response selection to all items.

Data analysis

All interviews were audio-recorded and professionally
transcribed. The transcripts were entered into ATLAS.ti
(version 7.1.7), a software program used for analysis of
qualitative research data [24].
Concept elicitation data were reviewed utilizing a content analysis approach to identify themes that described
important concepts raised by subjects [25]. Words and
phrases provided by subjects to describe symptom
concepts were coded and grouped into key themes and
relationships. Data from interviews were also analyzed
with the goal of comparing and tallying the amount of
novel information that was observed in each interview.
Interviews were coded in the order in which they were
conducted and then grouped sequentially into quartiles
[25]. Analysis was conducted to determine whether conceptual saturation–defined as the point at which no new
concepts emerge with the addition of more interviews
[26–28]—was achieved. A saturation table was created
to track emergent information from subjects and
analysis was undertaken in a phased approach [29].
Specifically, each new group (quartile) of transcripts
was assessed in an ongoing fashion for the appearance
of new concept codes [25]. Once no newly appearing
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codes were documented, saturation was considered
achieved.
Following analysis of the concept elicitation transcripts,
these data were discussed with clinical experts and instrument development experts, and a draft version of
the COPD-MSD was developed, including its instructions, 32 candidate items and response scales. The draft
COPD-MSD was then refined based upon feedback from
a translatability and readability assessment.
Twenty-one cognitive interviews were conducted with
a new sample of COPD subjects using the draft COPDMSD. Content analyses were also applied to the cognitive interview data, focusing on subject responses to the
comprehension of items in the COPD-MSD, salience of
the content to their COPD symptom experiences, ease
of completion of the COPD-MSD, and subject suggestions regarding item language, instructions, response
scales, and formatting. The same experts who participated in the generation of the initial draft COPD-MSD
reconvened to review the cognitive interview data and
come to a consensus on needed revisions to the COPDMSD. Two rounds of minor revisions occurred following
this meeting, ultimately leading to the COPD-MSD in
its current form (see Table 6).

Results
Concept elicitation
Concept elicitation study sample

The mean age of the concept elicitation sample was
65.0 years (±7.5). Approximately half (n = 17, 49 %) were
female and a majority (n = 28, 80 %) self-identified as
white and four subjects (11 %) identified as Hispanic.
Subjects represented the full range of COPD severity
with 5 subjects (14 %) classified as GOLD I, 11 (31 %) as
GOLD II, 11 (31 %) as GOLD III, and 8 (23 %) as GOLD
IV. Complete sociodemographic and clinical characteristics are included in Table 1. Subject responses to the
PRO measures (CAT, mMRC and SGRQ-C) indicated
that the sample generally experienced moderate to high
levels of impairment due to COPD (Table 1).
Concept elicitation findings

Morning symptom descriptions and concept saturation At the outset, subjects were given the opportunity to discuss freely what morning symptoms they
experienced as a result of COPD. Prompting and
probing from interviewers were minimal at the opening of the interview to allow for as much spontaneous
reporting as possible. Following this, interviewers
reviewed a checklist of symptoms with subjects to
confirm that they experienced no additional morning
symptoms related to COPD. In addition to exploring
morning symptoms, interviewers asked subjects about
sleep disturbance due to COPD symptoms. Some
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Table 1 Subject sociodemographic, clinical, and outcome
characteristics
Characteristica

CE (N = 35)

CI (N = 21)

65.0, 7.5
(51–75)

62.3, 8.3
(44–75)

17 (49)

10 (48)

Age (years)
Mean, SD, (range)
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Table 1 Subject sociodemographic, clinical, and outcome
characteristics (Continued)
Patient-reported SGRQ-C,
mean, SD (range)f

Gender n (%)
Female
Racial/Ethnic Background
n (%)
28 (87)

13 (62)

4 (11)

4 (19)

Hispanic or Latino

4 (11)

4 (19)

Otherb

3 (9)

4 (19)

15 (43)

9 (43)

Employment Status
n (%)

Disabled

9 (26)

8 (38)

Full-time work

6 (17)

1 (5)

Part-time work

3 (9)

2 (10)

Otherc

2 (7)

1 (5)

Highest Level of Education
Completed n (%)
≤ Secondary/high school

15 (43)

7 (33)

Associate degree

2 (7)

4 (19)

Some college

7 (20)

6 (29)

College degree

9 (26)

2 (10)

2 (7)

2 (10)

Current smoker

15 (43)

3 (14)

Former smoker

20 (57)

18 (86)

Other

Current or Former Smoker
n (%)

Physician-reported GOLD Stage,
n (%)
GOLD I

5 (14)

2 (10)

GOLD II

11 (31)

8 (38)

GOLD III

11 (31)

7 (33)

GOLD IV

8 (23)

4 (19)

0

0 (0.0)

0 (0.0)

1

12 (34.3)

7 (33.3)

2

18 (51.4)

5 (23.8)

3

5 (14.3)

7 (33.3)

4

0 (0.0)

2 (9.5)

22.0, 6.2
(11–32)

20.1, 8.6
(5–36)

Physician-rated mMRC,
n (%)

Patient-reported CAT total score
Mean, SD (range)e

–

71.8, 17.3 (25–100)

–

Activity

66.9, 24.3 (0–100)

–

Impact

46.6, 22.5 (0–99)

–

All characteristics self-reported by subjects unless otherwise noted
Other: CE – Chicano (n = 1), Hispanic (n = 2); CI – Chicano (n = 3),
Hispanic (n = 1)
c
Other: CE – Homemaker (n = 1); Self-employed (n = 1);
CI – Unemployed (n = 1)
d
Other: CE – Postgraduate degree (n = 1); 4 years, no degree (n = 1);
CI – Postgraduate degree (n = 2)
e
CAT score ranges from 0-40 with scores ≥ 10 indicating the patient is
symptomatic and >20 indicating high impairment
f
SGRQ total and subscale scores range from 0-100 with higher scores
indicating more impairment
b

Black or African American

d

57.2, 19.9 (4–100)

Symptom

a

White

Retired

Total score

subjects spontaneously mentioned nighttime awakenings prior to the interviewer probing on this experience. Saturation of all concepts was achieved in the
first 19 interviews – no new symptom concepts arose
in the last 16 interviews that had not arisen in the
first 19 interviews (see Table 2).
Table 3 presents the most frequently cited morning
symptom concepts and is organized by subject quartile with the number of spontaneous versus probed
reports noted. The most commonly reported symptom was shortness of breath, which was spontaneously mentioned by all 35 subjects. Other commonly
reported (spontaneously and probed) symptoms included: phlegm (n = 31, 89 %); cough (n = 30, 86 %);
wheeze (n = 24, 69 %); and chest tightness/discomfort
(n = 22, 63 %). Other symptoms endorsed by subjects
were nighttime awakening/sleep disturbance (n = 16,
46 %), headache (n = 12, 35 %), and exhaustion/tiredness (n = 8, 23 %). Other symptoms were mentioned
by subjects, however these were reported with very
low frequency (n ≤ 5) and were not raised by all four
quartiles of subjects; as such, they were not included
in Table 3. Forty-two percent (10 out of 24) of the
subjects who mentioned wheezing did so without being prompted by the interviewer. A similar proportion
of the subjects (7 out of 16) who mentioned nighttime awakening reported it spontaneously. Only one
third of subjects who endorsed headaches did so
spontaneously. It is important to note that the concept of exhaustion or feeling tired was not included
on the interviewer’s symptom checklist, thus all reports of this symptom were spontaneous. Had fatigue
or exhaustion been included on the checklist, the
total number of reports (probed and spontaneous)
likely would have been much higher.

Additional Symptom Conceptsa

Core Symptom Concepts

SOB Cough Phlegm Chest Wheeze Trouble Headache Fatiguec Back Dizzinessd Congestione Weak Nasal
Heart
Foot/
Dry
Painb
Sleeping
Pain
Legsf Drainage Palpitations Ankle
Mouth
Swelling

Tight Numb Inability
Throat Face, to Think,
Lips
Reason

Group 1 (n = 9)
102-002

S

P

S

102-015

S

102-018

S

102-028
102-033

S

S

S

S

S

S

S

S

S

S

S

S

S

S

S

102-035

S

S

S

S

104-001

S

S

S

104-004

S

S

S

104-006

S

S

S

103-003

S

S

S

S

S

103-011

S

S

S

S

P

104-008

S

S

S

S

104-011

S

S

S

P

105-001

S

S

S

S

105-002

S

105-003

S

S

S

105-005

S

S

S

P

P

105-006

S

S

S

S

P

103-009

S

S

S

103-012

S

S

S

106-004

S

P

P

106-006

S

106-007

S

S

P

106-010

S

S

S

106-015

S

S

S

S

106-016

S

106-017

S

S

S

P

P
S
P
S

S

P

S

P

S
S

S

S

S
S

S

P
P

P

S
S

S

S

S

P

S

P

S

S

S

S

P

Group 2 (n = 9)

P

S
S

S
S

S
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Table 2 Saturation of symptom concepts

S
S

P

S
S

S

P

Group 3 (n = 9)

S

P

P

P

S

P

P

P

P

S

S

S

S

S

P

P
P

S

S

S
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S

Group 4 (n = 8)
102-036

S

P

P

102-040

S

S

S

P

102-039

S

S

S

S

P

S

102-037

S

S

P

S

S

S

108-002

S

S

S

108-003

S

P

P

108-006

S

S

P

108-007

S

Spontaneous

35

27

Probed

0

3

TOTAL (S + P)

35

30

P

S

P
S
P

S

S

P

P

P

S

S

24

16

10

7

4

8

4

3

5

3

2

1

1

1

1

1

1

7

6

14

9

8

0

0

0

0

0

0

0

0

0

0

0

0

31

22

24

16

12

8

4

3

5

3

2

1

1

1

1

1

1

S

These “additional concepts” were not included in the symptom checklist used by interviewers, thus these concepts were not probed for by the interviewer rather they spontaneously emerged from subjects
b
Includes “chest tightness” and “chest discomfort”
c
Includes “exhaustion,” “lack of energy,” “tiredness,” “malaise” and “weakness”
d
Includes “lightheadedness”
e
Includes “nasal stoppage”
f
Includes “legs dragging”
a
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Table 2 Saturation of symptom concepts (Continued)
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Table 3 Most frequently cited morning symptoms by subjects (Concept Elicitation)
SOB

Phlegm

Cough

Wheeze

Chest Tightness/
Discomfort

Nighttime Awakening/
Sleep Disturbance

Headache

Exhaustion/
Tiredness

Group 1 (n = 9)

✓

✓

✓

✓

✓

✓

✓

✓

Group 2 (n = 9)

✓

✓

✓

✓

✓

✓

✓

✓

Group 3 (n = 9)

✓

✓

✓

✓

✓

✓

✓

✓

Group 4 (n = 8)

✓

✓

✓

✓

✓

✓

✓

✓

Spontaneous (S)

35

24

27

10

16

7

4

8

Probed (P)

0

7

3

14

6

9

8

0

Total (S + P)

35

31

30

24

22

16

12

8

Subject terminology for morning symptoms The
phrase “shortness of breath” was used spontaneously by
18 subjects (51 %). Other terms included “difficulty/
trouble breathing” (n = 6), “hard to breathe/can’t hardly
breathe/can’t breathe” (n = 6), “trouble catching breath/
can’t get breath” (n = 3), and “out of breath/run out of
air” (n = 2). Activity level and/or the difficulty or level of
effort required to breathe were frequently raised when
talking about shortness of breath. More so than any
other COPD symptom discussed, it was clear that the
severity of a subject’s shortness of breath was closely tied
to the type or level of physical activity in which a subject
was engaged.
All subjects used the term “cough” when describing
the phenomenon of coughing. As subjects spoke about
coughing, they generally described the type of cough
they experienced (i.e., “heavy,” “hard,” “deep,” “easy,”
“dry,” and “productive”). The effort required to cough
was frequently mentioned. For all symptoms, but especially so with cough, subjects had a difficult time differentiating between frequency and severity. For example,
frequency of cough was directly linked to how subjects
viewed the severity of their cough (if one is coughing
frequently, their cough was severe). Subjects also discussed the idea of “coughing fits” or “attacks” or relatively intense episodes of cough. Given this feedback, it
was later decided that three separate questions would be
developed for cough (frequency, severity, and number of
coughing attacks) to ensure full coverage of the symptom experience.
Of the 31 subjects who reported experiencing phlegm
or mucus, “phlegm” was the most common term spontaneously mentioned with 20 subjects (65 %) using this
word. The next most common term spontaneously reported was “mucus” with seven subjects (23 %) using
this word. Although “phlegm” was spontaneously mentioned by a majority of subjects, analysis showed that a
number of subjects often mentioned both terms and
would utilize them interchangeably. Subjects described
phlegm in terms of consistency, thickness, and/or color,
amount/quantity, and the effort required to cough it up.
When analyzing symptom co-occurrence in the

transcripts, phlegm was frequently raised by subjects in
conjunction with discussion of other symptoms, most
notably with cough (225 times), underscoring the proximity of these two symptoms.
Many subjects mentioned the concept of congestion when
discussing phlegm which implies that these represent the
same or at least closely related concepts to patients. Conversely, several subjects discussed phlegm and congestion as
distinct concepts. This informed the development of a
separate question in the COPD-MSD for chest congestion.
Twenty-two subjects endorsed experiencing chest
tightness or discomfort. Subjects used a variety of words
to describe the concept spontaneously with the most
common being “chest tightness” (n = 12, 55 %). Some
subjects would discuss them separately while others used
the terms interchangeably. For example, when asked by
the interviewer if she/he experienced chest pain or tightness with coughing, one subject commented “tightness
but not pain, tightness.” However, other subjects would
often dwell on the sense of pain or discomfort associated
with breathing or coughing and would link that with
tightness. Given the seeming overlap between tightness
and discomfort, they were combined for analysis and
tallying purposes. It was later decided that a separate
question in the COPD-MSD for each concept would be
prudent in the early stages of instrument development.
Similar to cough, there were no other words used by
subjects to convey the symptom concept of “wheeze.” Of
the 24 subjects who endorsed this symptom, all used the
term “wheeze.” When discussing this in detail, a number
of subjects mentioned hearing their breathing and used
words like “whistle,” “squeaky,” and “rattle” to describe
the sound.
Of the 16 subjects who discussed having trouble sleeping or waking up in the middle of the night, most
expressed difficulty breathing when attempting to sleep
and/or waking up due to coughing fits. A number of
subjects (n = 8) clearly linked trouble sleeping with their
COPD symptoms, but a few subjects (n = 4) were not
certain if their sleep issues were related specifically to
their COPD. Several other subjects (n = 4) mentioned
reasons other than COPD symptoms (e.g., anxiety) as
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the contributing factor to their sleep disruptions. Eight
subjects mentioned feeling a general lack of energy or
exhaustion. These were all spontaneous reports as interviewers did not probe for this symptom. Subjects described this concept with a variety of words, including
“exhausted,” “wore out,” “malaise,” and “tired/tired out.”
Subjects sometimes linked this symptom directly to their
interrupted sleep.

Morning activities that trigger or worsen symptoms
Subjects were asked to discuss if and how their morning
activities impacted their COPD symptoms. Specifically,
subjects were asked if any of their morning activities
triggered or worsened their symptoms (Table 4). Many
varied morning activities (and movements) were mentioned by subjects, however all activities generally fell
into 1 of 5 categories: routine indoor physical activity,
routine outdoor physical activity, getting oneself ready,
general housework, and miscellaneous strenuous activity. Examples of activities that fell into these categories
are footnoted in Table 4. Almost all subjects (n = 33)
spontaneously discussed 1 or more common indoor
morning activities or routines that would trigger their
COPD symptoms (e.g., going up and down stairs).
Subjects were asked to rank the top 3 activities that affected their COPD symptoms in the morning. Routine
indoor physical activity typically performed in the morning (e.g., getting out of bed, walking/moving around the
home) was ranked as number one more than any other
kind of activity (n = 14) and also fell into the top three
list most often with all subjects (n = 32) ranking at least
one routine indoor activity somewhere in their top three
list. Subjects were then asked which symptoms were impacted by each of their top three activities. Shortness of
breath more so than any other symptom was noted by
subjects as being affected by their top three activities.
This again underscores the close link between physical
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activity or movement with breathlessness (data not
shown).
Item generation

Based upon close review of these qualitative data, a
draft version of the COPD-MSD, including its instructions, 32 candidate questions, and response
scales was developed by a group of clinical experts
and instrument development experts who convened in
September 2013. Key discussion and decision points
that informed the COPD-MSD’s content are included
in Table 5. The draft was reviewed by a translation and
cultural specialist and edits were made for clarity and
translatability. The revised draft COPD-MSD was assessed
in a new sample of 21 COPD subjects using cognitive
interview methodologies.
Cognitive interview

For brevity, the cognitive interview results presented
below relate only to the content that ultimately was
retained in the final 19-item version of the COPD-MSD
(Table 6).
Cognitive interview study sample

The mean age of the cognitive interview sample was
62.3 years (±8.3). Half were female (n = 10, 48 %) and a
majority (n = 13, 62 %) identified as white. Subjects represented the full range of COPD severity with two subjects (10 %) classified as GOLD I, eight subjects (38 %)
as GOLD II, seven subjects (33 %) as GOLD III, and
four (19 %) classified as GOLD IV. Complete sociodemographic and clinical characteristics are in Table 1.
Subject responses to the PRO measures (CAT, mMRC)
indicate that these subjects had moderate to high impairment due to their COPD (Table 1). To alleviate subject burden and shorten the study visit, cognitive
interview subjects were not administered the SGRQ-C.

Table 4 Activities that trigger or worsen COPD symptoms (Concept Elicitation)
Routine Indoor
Physical Activitya

Routine Outdoor
Physical Activityb

Getting Oneself
Readyc

General
Houseworkd

Miscellaneous
Strenuous Activitye

Group 1 (n = 9)

✓

✓

✓

✓

✓

Group 2 (n = 9)

✓

✓

✓

✓

✓

Group 3 (n = 9)

✓

✓

✓

✓

✓

Group 4 (n = 8)

✓

✓

✓

✓

Spontaneous

33

18

11

12

20

Probed

2

7

13

11

0

Total (S + P)

35

25

24

23

20

a

Routine indoor activity: going up/down stairs, walking/moving around house, getting out of bed, preparing food/coffee
b
Routine outdoor activity: walking dog, picking up newspaper/mail, yard work, sweeping, fishing
c
Getting oneself ready: bathing/showering, getting dressed, going to bathroom, putting on socks, tying shoes
d
General housework: vacuuming, cleaning, doing laundry, making bed, setting/clearing table
e
Miscellaneous strenuous activity: lifting/carrying things, morning exercise (e.g., yoga, elliptical, treadmill)
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Table 5 Key notes from item generation expert panel meeting
(September 2013)

Table 6 COPD-MSD items and response scales

Notes/Group Decisions

Items asking about “this morning”

• It is difficult for subjects to link nighttime awakenings to symptoms,
thus do not ask subjects to report number of awakenings related to
symptoms; one advisor suggested adding a proxy item to capture
nighttime awakenings (“How rested did you feel this morning?”) – this
item would be in addition to a question regarding how tired or
fatigued the subject felt
• All symptom concepts, including those with relatively low subject
endorsement (e.g., headaches, exhaustion/tiredness), should be
included; advisors agreed to err on side of inclusivity in the early stages
of instrument development. It was noted items that perform poorly
would drop out in the future based on psychometric assessments
• Wheeze was debated at length among advisors with some noting it
was a difficult symptom to measure, however advisors agreed to
include wheeze for now with potential for deleting later
• Although unclear if “chest congestion” was viewed by subjects as a
distinct symptom from phlegm or other chest symptoms (i.e., tightness,
discomfort), include as separate item for now

COPD Item

Response Rangea

AM 1

SOB upon getting out
of bed

No SOB → Unable to because of SOB

AM 2

SOB while washing self

No SOB → Unable to because of SOB

AM 3

SOB while using arms
to do things

No SOB → Unable to because of SOB

AM 4

SOB while getting
dressed

No SOB → Unable to because of SOB

AM 5

SOB while bending over

No SOB → Unable to because of SOB

AM 6

SOB upon moving
around the home

No SOB → Unable to because of SOB

AM 7

Coughing attacks

0 → More than 5

AM 8

Frequency of cough

Not at all → Almost constantly

AM 9

Severity of cough

Did not cough → Very severe

AM 10 Amount of phlegm

None → Very large amount

AM 11 Difficulty bringing up
phlegm

Did not have phlegm → Very difficult

• Shortness of breath (but not other symptoms) should be measured in
the context of performing activities, however need to select activities
that are relatively universal; advisors recommended reviewing literature
and exploring this with subjects in cognitive interviews

AM 12 Severity of chest
tightness

No chest tightness → Very severe

AM 13 Severity of chest
discomfort

No chest discomfort → Very severe

• Advisors concluded a Likert scale would be best suited for the
COPD-MSD items

AM 14 Severity of chest
congestion

No chest congestion → Very severe

• Key questions or themes to explore during cognitive interview phase:

AM 15 Severity/amount of
wheezing

Not at all → Very much

AM 16 Feeling tired

Not at all → Extremely

AM 17 Feeling rested

Not at all → Extremely

• For those miscellaneous symptoms that were mentioned infrequently
(n < 5) and were not clearly related to COPD (e.g., back pain), advisors
agreed to exclude from COPD-MSD

o Explore subject language used around the “tiredness/exhaustion”
concept as well as how subjects describe and define “chest congestion”
(i.e., is chest congestion different from chest tightness and chest
discomfort?)

Items asking about “last night, after going to bed”

o Explore what morning activities are universal or common to all
subjects

PM 1

Severity/amount
of wheezing

Not at all → Very much

• For recall period, ask about morning timeframe in general, do not limit
or narrow to a specific hour within the morning period

PM 2

Sleep disturbance

Not at all → Very much

Cognitive interview findings

Overall, subjects reported that the COPD-MSD covered
their full range of morning COPD symptoms and was
easy to complete. On average, subjects completed the
32-item COPD-MSD within 8 min. A majority (n = 18,
86 %) said the COPD-MSD was relevant to and covered
their morning symptoms. Seven subjects (33 %) recommended adding one or two items, including: a question
on strength of cough (e.g., how violent are the coughing
attacks), and dry mouth, and a specific question on level
of exertion or physical activity (e.g., walking up hill),
and question about the impact of COPD symptoms
(e.g., sexual activity). Importantly, no new symptom
concepts emerged from the cognitive interviews, further supporting that conceptual saturation had been
achieved in the concept elicitation interview phase.
Instructions and recall period A majority of subjects
(n = 17, 81 %) understood and followed the COPD-

Abbreviations: COPD-MSD Chronic Obstructive Pulmonary Disease – Morning
Symptom Diary, SOB shortness of breath
a
The six SOB items utilize a 6-point response scale while all other items use a
5-point range

MSD’s morning instructions. Two subjects (10 %) recommended changing the recall period to the past week,
stating that a week would be a better evaluation period
of their good and bad days with symptoms.
Shortness of breath items All subjects (n = 21, 100 %)
reported that at least one of the activities of the seven
shortness of breath items triggered breathlessness. Bending over (n = 19, 91 %), moving around the home (n =
17, 81 %), getting dressed (n = 16, 76 %), and making the
bed (n = 15, 71 %) were the most commonly reported activities that triggered shortness of breath. The activities
in the shortness of breath items generally were reported
as being a part of subjects’ typical morning routine.
However, one subject (5 %) bathed at night rather than
the morning and one subject was confined to a
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wheelchair which influenced how he/she answered these
questions and thought about physical activities in general. Approximately two thirds of subjects (n = 14, 67 %)
stated that making the bed was a typical part of their
routine, while seven subjects (33 %) said that it was not
and/or that their partner would usually make the bed.
Of the latter, a majority were men (n = 5) indicating a
potential gender bias regarding responsibilities around
making the bed. Two subjects (10 %) reported that they
were unable to make their bed due to shortness of
breath. Note the item on making the bed (How severe
was your shortness of breath while making the bed this
morning?) was removed following the cognitive interviews and discussion with clinical and instrument
experts.
When talking about their morning activities, a majority of subjects (n = 17, 80 %) described how two or
more of the seven shortness of breath activities overlapped with one another. For example, “bending over”
and “getting dressed” were the activities most commonly mentioned in conjunction with one another.
Subjects typically stated that they would bend over to
put their socks and shoes on. “Using your arms to do
things” was another activity that subjects commonly
reported in connection with other morning activities,
including “making the bed,” “getting dressed,” and
“washing.” Several subjects (n = 4, 19 %) said they
avoided bending over to prevent triggering their
shortness of breath.
Subjects recommended adding examples to help clarify
a few of the morning activity items. A majority of subjects (n = 13, 62 %) suggested adding an example for the
“using your arms to do things” item, including: reaching
arms above head, cooking, and lifting objects. Approximately half of the sample (n = 10, 48 %) suggested adding an example for the item about bending over and
several subjects (n = 3, 14 %) suggested including an example for “moving around the home.”

Cough items Nearly all subjects (n = 19, 90 %) understood the cough items. One subject (5 %) had difficulty
differentiating between duration and frequency of their
cough and suggested defining the duration of a coughing
attack. Most subjects described the phrase “coughing attack” as a constant and persistent cough. A few subjects
(n = 3, 14 %) suggested changing the term “coughing attack” to “constant coughing” or just “coughing.”
A majority of subjects (n = 13, 62 %) viewed the item
on coughing attacks and the item on how often one
coughed as asking about different concepts. Similarly, a
majority of subjects (n = 16, 76 %) viewed the items
“how often did you cough” and “how severe was your
cough” as questions about different concepts.
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Phlegm/mucus items All subjects (n = 21, 100 %) demonstrated an understanding of the phlegm items by discussing what each item meant based on their personal
experiences. Almost all subjects (n = 18, 86 %) viewed
these items as asking about different concepts.
Chest symptom items All subjects (n = 21, 100 %)
understood the chest symptom items. Notably, over half
of the sample (n = 14, 67 %) said at least two of the four
chest items were asking about the same symptom with
nine subjects (43 %) stating that chest tightness and
chest discomfort represented the same issue.
Tired and rested items All subjects (n = 21, 100 %) demonstrated an understanding of the tired and rested items,
though over half the sample (n = 12, 57 %) reported that
the two items were asking about the same concept.
Nighttime instructions and recall period Almost all
subjects (n = 18, 86 %) understood the nighttime instructions, stating the section was asking them to think about
symptoms after going to bed. Several subjects (n = 4, 19 %)
mentioned that the instructions were unnecessary given
that the items themselves clearly stated the recall period.
Nighttime items All subjects (n = 21, 100 %) understood the intended meaning of the nighttime wheeze
item and nearly all subjects (n = 19, 90 %) understood
the sleep disturbance item. Two subjects (10 %) thought
the phrase “lung symptoms” encompassed COPD symptoms as well as other respiratory conditions such as lung
cancer. A few subjects (n = 3, 14 %) mentioned using
oxygen at night and two of these subjects specifically
stated that this alleviated their symptoms (i.e., impacted
the way they responded to the item).
Response options Overall, subjects understood the response options for all COPD-MSD items and could
identify that they represented scales of increasing intensity or severity. A number of subjects seemed to struggle
with differentiating between at least two response
choices, most frequently at the more severe end of the
scale. For example, about a third of subjects (n = 8,
38 %) stated that the options “severe” and “very severe”
were the same when discussing the cough severity item.
Another example of this was demonstrated with the
tired and rested items where eight subjects (38 %) said
that “very” and “extremely” had the same meaning for
these items. For the wheeze item, subjects struggled to
differentiate between options in the middle of the scale
with nine subjects (43 %) stating “a little” and “somewhat” were the same. The number of subjects who
struggled with differentiating between response options
varied by the diary item and response scale.
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Changes made to COPD-MSD following data review
by clinical and instrument experts Issues noted by
subjects were flagged for discussion with clinical experts
and instrument development advisors. Several changes
were made to the COPD-MSD following close review
and discussion of the cognitive interview data. These
changes are summarized in the paragraphs that follow.
1) It was initially concluded by the item generation
team of experts that the early version of the COPDMSD should err on the side of inclusivity rather
than exclusivity, thus the version of the COPD-MSD
that was tested in the cognitive interviews included
questions related to both morning and nighttime
symptoms. Following the cognitive interviews, it was
clearer that the nighttime symptoms, while important to subjects, did not appear to be interrelated to
their morning symptoms. While this left the opportunity to develop two separate measures, it was not
consistent with the key aim of developing the
COPD-MSD (i.e., assessment of morning symptoms)
and so most nighttime items were removed with the
exception of an item on nighttime wheeze and one
on general sleep disturbance. The nighttime wheeze
and sleep disturbance items were retained for further
study, based on recommendations from clinical advisors. Specifically, nighttime wheezing was discussed
as being a particularly important or challenging
symptom for subjects based on findings from a large
observational study conducted by Kessler et al. [7],
thus advisors suggested retaining this item and
tracking its performance in future studies.
2) Given the lack of consistency and potential gender
bias around making the bed in the morning, this
item was removed but “making the bed” was added
as a parenthetical example in the “using your arms
to do things” item.
3) It was determined that headache was not endorsed
sufficiently enough by subjects nor was it linked
consistently to COPD; therefore the two items
related to headache were removed.
4) The version of the COPD-MSD that was tested with
subjects in the cognitive interviews included two
global questions and several items on use of shortacting inhalers. It was decided that these items were
not necessary or appropriate to maintain as part of
the final version of the COPD-MSD. Global items
will be administered separately from the COPDMSD when it comes time to evaluate the psychometric properties of the COPD-MSD. Similarly,
questions on short-acting inhaler use will be developed and administered separately from but in conjunction with the COPD-MSD in future clinical trial
settings.
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Based on results of the cognitive interviews, the
COPD-MSD was significantly streamlined, reducing the
number of items from 32 to 19.

Discussion
This paper describes the methods and results of qualitative research conducted to assure content validity of the
COPD-MSD, a new daily diary for evaluating morning
symptoms of COPD. A review of the literature confirmed the need for this instrument and informed the
development of an interview guide for concept elicitation interviews during which patients with COPD were
asked to describe the type and nature of their morning
symptoms. Key symptoms reported by study subjects included shortness of breath with activity, cough, phlegm,
chest tightness, chest congestion, chest discomfort,
wheeze, fatigue, and impaired sleep quality. These symptoms align with those identified in the literature [2, 4, 8,
30, 31] and as outlined by the most recent GOLD report
[3]. A 32-item draft version of the COPD-MSD was
tested in a new set of COPD subjects using cognitive
interview methodology. Based on these patient insights
and input from clinical experts and instrument development advisors, the diary was refined to yield the final
19-item COPD-MSD.
The prevalence of morning symptoms and the impact of
those symptoms on subjects’ ability to perform routine
morning activities was confirmed in the study interviews
and are in agreement with findings and conclusions drawn
by other researchers in this area [7, 9, 10] and thus supported the decision to develop an instrument that focused
on the morning symptom experience in this subject population. The recent development and psychometric validation of the EMSCI which assesses early morning
symptoms and impact also demonstrates a growing interest and emphasis on this critical time of day for COPD
subjects. The items resulting from this qualitative work
closely mirror symptoms captured by the E-RS scale suggesting that these truly represent the symptoms most important to COPD subjects. The new COPD-MSD
instrument possibly could be administered as a
complimentary measure to the EXACT/E-RS [18, 19] in a
clinical trial setting with the COPD-MSD being used to
measure the morning symptom experience and the E-RS
each evening to capture subject symptoms over the previous 24 h period.
As evidenced by input from subjects, there appeared
to be some conceptual overlap between the “tired” and
“rested” questions. The “How tired did you feel this
morning?” item was driven by insights collected during
the concept elicitation interviews and was based on subjects who reported feeling tired, fatigued or exhausted in
the mornings due to their COPD symptoms. The “How
rested did you feel this morning?” item was added
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following a discussion with advisors about how best to
capture nighttime awakenings. One advisor commented
that it is difficult for subjects to link awakenings to specific symptoms and therefore suggested asking about
how well rested subjects felt as a proxy for nighttime
awakenings. It is likely that one of these items will be removed based upon quantitative results from a larger,
psychometric validation study (i.e., items will likely demonstrate high inter-item correlations and confirm redundancy in concept coverage).
An interesting finding was related to patient descriptions of chest symptoms and their use of terminology to
describe these experiences. Subjects used terms such as
“chest tightness,” “chest discomfort,” “chest congestion,”
“phlegm,” and “wheeze” with a personal understanding
of each. Some subjects used these terms interchangeably,
while others had a unique definition for each. Wheeze
was described as a sound or noise, with varying interpretation. This symptom may be more relevant and interpretable to patients with asthma or those with COPD
and reversible airflow obstruction. Quantitative data are
needed to examine these items further, including their
individual performance properties, inter-item correlations, factor structure, and relationship to socioeconomic and clinical characteristics. Based on these
analyses, it may be appropriate to drop one or more of
the items.
Three subjects (14 %) described how taking their rescue inhaler or nebulizer in the morning would reduce
the severity of their shortness of breath as their morning
routine progressed. Even though the impact of taking
medication in the morning was only mentioned by a few
subjects, these comments could have important implications for future clinical trial implementation and administration of the COPD-MSD. Specifically, the timing
around use of the morning inhaler as well as the timing
of COPD-MSD administration needs to be carefully conveyed in order to avoid introducing bias that could affect
subjects’ responses to the COPD-MSD. Several subjects
commented that their nighttime oxygen treatment
would or did affect how they responded to the COPDMSD, suggesting this will also need to be addressed in
clinical trial implementation and logistics.
Subjects who took part in these concept elicitation
and cognitive interviews represented the complete range
of COPD severity (GOLD I–IV), varying levels of educational achievement, race and ethnicity, and both genders
were equally represented. However, it should be noted
that these interviews were conducted among subjects
who had a history of smoking and who had been relatively symptomatic at the time of screening for the
study. The relevance and ability of the COPD-MSD to
fully capture the experience of never smokers or individuals who are less symptomatic has yet to be evaluated.
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The main limitation of this study was that only a single round of cognitive interviews was conducted. The instrument development process would have been
strengthened by an additional round of cognitive interviews among a small sample of COPD subjects to confirm that the streamlined, 19-item COPD-MSD was
accepted and understood by these subjects. Additional
interviews also may have helped to further clarify patient
perceptions of chest tightness and discomfort, chest congestion and phlegm.
The next phase of development and validation for the
COPD-MSD will involve the application of quantitative
methods to reduce the length of the instrument, including item-level descriptive statistics (floor and ceiling effects, level of missingness), item-to-item and item-tototal correlations, and the use of Rasch and factor analyses. With the instrument content and structure finalized, COPD-MSD scores will be tested for reliability,
validity, and responsiveness to change. These analyses
could be performed in a separate observational validation study or through secondary analyses of data from a
clinical trial.

Conclusions
Research indicates that mornings tend to be the most
symptomatic period of the day for patients with COPD.
A measurement tool that can quantify this experience
could be useful for understanding the benefit of new
medicines. Qualitative research involving patients with
COPD and input from clinical and measurement experts
yielded the 19-item COPD-MSD, ready for quantitative
testing.
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